Summary of Key Points from the Global Healthcare Conference Call Industry Overview - **Healthcare Sector Performance**: The healthcare sector has underperformed, with a year-to-date increase of only 3% compared to the S&P 500's 13% increase. Sub-sector performance varies significantly, with Biotech up 16%, Pharma up 4%, and Managed Care down 25% [1][11][12]. - **S&P 500 Weighting**: The healthcare sector's weighting in the S&P 500 has dropped to approximately 9.1%, the lowest since 1994, compared to 16% two and a half years ago [1][11]. Core Insights and Arguments - **Optimism for 2026**: Despite recent challenges, there are signs of optimism for 2026, with expectations of improved demand and sentiment in the healthcare sector [1][9][46]. - **Biopharma M&A Activity**: M&A volumes in the biopharma sector are expected to exceed those of the second half of 2024, driven by the need to fill clinical pipelines [2][21]. - **Impact of Tariffs**: Tariffs have been a persistent issue affecting U.S. MedTech, with valuations fluctuating. The S&P Equipment & Supplies Index P/E is around 1.0x, down from a 10-year average of 1.26x [3][30]. - **Life Sciences Uncertainty**: There remains uncertainty in the life sciences sector, with management teams focusing on NIH budget changes and global tariffs as key factors influencing demand [4][46]. Additional Important Insights - **China as an Innovation Hub**: China is emerging as a global hub for biotech innovation, with low geopolitical risk, particularly for CROs with domestic exposure [6][29]. - **Healthcare Technology and Distribution**: This segment is relatively insulated from political risks but still faces challenges from drug pricing policies and potential Medicaid cuts [5][49]. - **AI Integration in MedTech**: The integration of AI in MedTech is increasing, with over 1,200 AI-enabled devices documented, indicating a significant technological shift in the industry [32][33]. - **Tariff and FX Impact on European MedTech**: In Western Europe, FY25 and FY26 EPS forecasts have decreased by 9% and 10% respectively, largely due to tariffs and foreign exchange impacts [36][38]. Key Themes and Stock Picks - **Top Picks by Sector**: - **U.S. Pharmaceuticals and Biotech**: LLY, VRTX, GILD [10]. - **U.S. SMID Cap Biotech**: ARGX [10]. - **U.S. MedTech**: BSX, EW, IRTC [10]. - **Western Europe MedTech & Life Sciences**: ALC, FRE-DE, SNN [10]. - **U.S. Life Sciences Tools & Diagnostics**: A, WST, GH [10]. - **China Healthcare**: Hengrui, Hansoh, Ascletis, Abbisko, Mindray, MicroPort Medbot, Wuxi Apptec, Wuxi Bio [10]. Conclusion - The healthcare sector is navigating through a challenging landscape marked by tariff impacts, policy uncertainties, and varying sub-sector performances. However, there are emerging opportunities, particularly in biopharma M&A and AI integration, which could drive growth as the sector moves into 2026.

As an example, in London, you'd buy a certain drug for $130 and even less than that, I guess $88 as of account a month ago. And in New York, you pay $1,300 for the same thing. So now we're going to be paying uh instead of 1300, you'll be paying about $150. And they'll be paying $150, too.We're going to pay the same thing. Favored nations. It's beautiful. It's a beautiful thing.and we've been ripped off by the whole world for a long period of time. >> You mentioned a $1,300 drug at the top of this. Were you ...